OPGx-RDH12

Preclinical

OOpus Genetics, Inc

OPGx-RDH12 is one of 2 therapeutic programs targeting Leber Congenital Amaurosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Leber Congenital AmaurosisNot yet recruiting

Leber Congenital AmaurosisPreclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Leber Congenital Amaurosis

#DrugCompanyPhaseTrials

Sepofarsen

PProQR Therapeutics

Phase 3

1 2

OPGx-RDH12

OOpus Genetics, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2034

PreclinicalNot yet recruiting

Leber Congenital Amaurosis

NCT07681778

Clinical

Trials by Indication[1]

Leber Congenital Amaurosis1 trial

A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subretinally Injected OPGx-RDH12 Administered in Participants With Leber Congenital Amaurosis With Autosomal-Recessive Retinol Dehydrogenase 12 Mutations

Not yet recruiting·OOpus Genetics, Inc·Preclinical·NCT07681778·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OPGx-RDH12. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for OPGx-RDH12. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Opus Genetics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: OOpus Genetics, Inc

OPGx-RDH12

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2034

Trials by Indication[1]

Leber Congenital Amaurosis1 trial

References

Drug Info

Quick Facts

Related News